There is one clinical trial.
"SKILLZ," is a mixed methods evaluation of the Grassroots Soccer (GRS) SKILLZ Package based in Lusaka, Zambia. The package is made up of three football-based programs: (1) SKILLZ-Girl - implemented in schools as part of a 10-week program culminating in a tournament event; (2) SKILLZ-Club - implemented as an ongoing extra-curricular activity after the completion of SKILLZ-Girl; (3) SKILLZ-Plus - a clinic based football group targeted at girls that are HIV-positive. The programs work together to build a continued support system which encourages uptake of Sexual Reproductive Health (SRH) and HIV services, while facilitating ART adherence (for HV-positive participants) and continued engagement with health services over the long-term (whether to contraceptive methods, HIV prevention services, HIV repeat testing, and/or HIV treatment and care). The study team has developed an enhanced SKILLZ-Girl offering, which will include a comprehensive module on HIVST, contraceptives and PrEP, access to a nurse during the implementation of sessions and the additional offering of HIVST and contraceptive services at the event along with ongoing engagement through the SKILLZ-Club program (Enhanced Arm) , The central hypothesis is that this enhanced curriculum will increase HIV testing and contraceptive uptake compared to the standard SKILLZ curriculum & standard event (SOC Arm). The investigators further hypothesize that the intervention in the enhanced arm will positively and directly affect a number of mediating factors including attendance at soccer events where community-based SRH services are offered, SRH knowledge, empowerment, self-confidence, and perceptions of gender balance, and (reduced) stigma. For girls found to be HIV-positive, the follow-on SKILLZ intervention (SKILLZ-Plus) has been designed to facilitate linkage to HIV care and treatment, reduce HIV-related stigma, increase disclosure to family and partners, increase feelings of social support, empowerment, self-efficacy, and ultimately adherence to ARVs, viral load suppression (VLS) and retention in HIV care and treatment. This study will be conducted in up to 32 secondary schools that GRS currently serves in the Lusaka Urban District.
Description: Number of participants, enrolled in the study, undergoing HIV testing (HIVST our Determine tests) over 2 years. Collected from facility testing registers and community testing registers.Measure: Number of participants undergoing HIV testing within 24 months Time: 24 months
Description: Number of participants, enrolled in the study, accessing contraception, PreP or PEP over 2 years. Determined through the electronic medical record and clinic registers.Measure: Number of participants accessing SRH related prevention services within 24 months Time: 24 months
Description: The percentage of participants, testing HIV positive, who have an undetectable viral load (as defined by the laboratory doing the test) after one year on treatment. Collected from routine laboratory data.Measure: The percentage of HIV infected participants being virally suppressed at 12 months Time: 12 months
Description: The percentage of participants, testing HIV positive, who are actively retained in care at 3 months ie are not more than 7 days late for a scheduled appointment. Determined using the electronic medical record.Measure: The percentage of HIV infected participants retained in care at 3 months Time: 3 months
Description: The percentage of participants, testing HIV positive, that have made their scheduled visit to the clinic within the first at 6 months of enrolment. (less than 7 days late), using the electronic medical record.Measure: The percentage of HIV infected participants retained in care at 6 months Time: 6 months
Description: The percentage of participants, testing HIV positive, who attend their scheduled visits within the first 12 months of enrolment (less than seven days late). determined through the electronic medical record.Measure: The percentage of HIV infected participants retained in care at 12 months Time: 12 months
Description: FGD's, IDI's and routine program data ( attendance registers, process data and documented observations) will be used to identify mediators, predictors, and barriers to uptake of the SKILLZ package after implementationMeasure: Conduct a process evaluation to describe how the intervention worked Time: 24 months
Description: Costs will include the personnel to manage the intervention, financial incentives and other related miscellaneous costs. These will be collected by the program manager and study team and will be based on actual costs.Measure: Average short-term costs for the program implementation based on net-costs for the intervention. Time: Baseline through 12 months
Description: Each session that is conducted will be documented including number of participants in attendance (assessed voia attendance registers and routine program data).Measure: Fidelity monitoring or adherence to the program as measured by the number of coaching sessions conducted per plan. Time: Baseline through 12 months
Description: Record and track key barriers through review of routine program data that prevent participants from engaging with the intervention. ie through review of the data collected by coaches from feedback from participants, FGD's and IDI's. During this COVID-19 period, we may be limited or may need to revise our anticipated collection of study results. The study record will reflect these changes as we navigate through the course of the study.Measure: Identify barriers that prevent intervention participation Time: Baseline through 12 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports